Press Releases

-FDA clears IND Application for Apraglutide for Acute Graft-Versus-Host Disease - Dosing of first patient expected in 1Q 2022 - - Interim data anticipated in 2H 2022 - - FDA previously granted orphan drug designation for apraglutide for the prevention of acute graft-versus-host disease - BASEL, ...

- Proprietary CoMET platform aims to treat severe rare Inherited Metabolic Diseases - BASEL, Switzerland, Sept. 21, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare ...

Company to host an R&D Day on September 21, 2021 BASEL, Switzerland, Sept. 16, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced upcoming ...

Biopharma veteran enhances VectivBio’s legal, regulatory and operational capabilities BASEL, Switzerland, Sept. 08, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare ...

Paul R. Carter and Murray W. Stewart Elected to the Board of Directors BASEL, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, ...

- Acquisition of Innovative Small Molecule Platform Significantly Expands Rare Disease Pipeline - - VectivBio to Host R&D Day on September 21, 2021- BASEL, Switzerland, Aug. 31, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company ...

BASEL, Switzerland, Aug. 12, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions, today published the invitation to the ...

- Industry veterans bring decades of clinical, regulatory and commercial management expertise to VectivBio - - Nominees will stand for election at an Extraordinary General Meeting of shareholders on September 2, 2021 - BASEL, Switzerland, July 12, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG ...

Phase 2 trial expected to begin in the first quarter of 2022 BASEL, Switzerland, June 24, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative ...

Phase 2 trial will evaluate the efficacy of once-weekly apraglutide in increasing intestinal energy absorption in CIC patients with SBS-IF CIC patients represent over half of the total SBS-IF population Initial readout of 4-week intestinal energy absorption data expected in 1H22 BASEL, Switzerland, ...